via Georgia State University
Treatment of SARS-CoV-2 infection with a new antiviral drug, MK-4482/EIDD-2801 or Molnupiravir, completely suppresses virus transmission within 24 hours, researchers in the Institute for Biomedical Sciences at Georgia State University have discovered.
The group led by Dr. Richard Plemper, Distinguished University Professor at Georgia State, originally discovered that the drug is potent against influenza viruses.
“This is the first demonstration of an orally available drug to rapidly block SARS-CoV-2 transmission,” said Plemper. “MK-4482/EIDD-2801 could be game-changing.”
Interrupting widespread community transmission of SARS-CoV-2 until mass vaccination is available is paramount to managing COVID-19 and mitigating the catastrophic consequences of the pandemic.
Because the drug can be taken by mouth, treatment can be started early for a potentially three-fold benefit: inhibit patients’ progress to severe disease, shorten the infectious phase to ease the emotional and socioeconomic toll of prolonged patient isolation and rapidly silence local outbreaks.
“We noted early on that MK-4482/EIDD-2801 has broad-spectrum activity against respiratory RNA viruses and that treating infected animals by mouth with the drug lowers the amount of shed viral particles by several orders of magnitude, dramatically reducing transmission,” said Plemper. “These properties made MK-4482/EIDD/2801 a powerful candidate for pharmacologic control of COVID-19.”
In the study published in Nature Microbiology, Plemper’s team repurposed MK-4482/EIDD-2801 against SARS-CoV-2 and used a ferret model to test the effect of the drug on halting virus spread.
“We believe ferrets are a relevant transmission model because they readily spread SARS-CoV-2, but mostly do not develop severe disease, which closely resembles SARS-CoV-2 spread in young adults,” said Dr. Robert Cox, a postdoctoral fellow in the Plemper group and a co-lead author of the study.
The researchers infected ferrets with SARS-CoV-2 and initiated treatment with MK-4482/EIDD-2801 when the animals started to shed virus from the nose.
“When we co-housed those infected and then treated source animals with untreated contact ferrets in the same cage, none of the contacts became infected,” said Josef Wolf, a doctoral student in the Plemper lab and co-lead author of the study. By comparison, all contacts of source ferrets that had received placebo became infected.
If these ferret-based data translate to humans, COVID-19 patients treated with the drug could become non-infectious within 24 hours after the beginning of treatment.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
- ICER Says No to Molnupiravir, Yes to Paxlovid and Fluvoxamine for Outpatient COVID Treatment
Merck’s oral COVID treatment molnupiravir lacks adequate evidence to support claims that it’s any more effective than symptomatic care.
- Is Paxlovid, the COVID pill, reaching those who most need it? The government won’t say
As the nation largely abandons mask mandates, physical distancing, and other covid-19 prevention strategies, elected officials and health departments alike are now championing antiviral pills. But the ...
- Is Paxlovid, the COVID Pill, Reaching Those Who Most Need It? The Government Won't Say
Pfizer’s Paxlovid pill, along with Merck’s molnupiravir, are aimed at preventing vulnerable patients with mild or moderate covid from becoming sicker or dying. More than 300 Americans still ...
- High-risk COVID-19 patients can now get two antiviral prescription drugs — but some are still missing out
It's the second antiviral drug to be listed on the PBS for people at high risk of severe COVID-19, following the addition of molnupiravir (also known as "Lagevrio") back in March. Both drugs ...
- CT has more than 12K free Paxlovid doses to treat COVID, but few people are taking it. Here’s why
Approved earlier this year under an emergency-use authorization, Pfizer’s Paxlovid and molnupiravir, developed by Ridgeback Biotherapeutics and Merck, are the first outpatient therapeutics ...
Go deeper with Google Headlines on:
Go deeper with Bing News on:
- A novel method for SARS-CoV-2 sentinel surveillance
In a recent study posted to the medRxiv* preprint server, researchers monitored coronavirus disease 2019 (COVID-19) transmission trends using a new sentinel surveillance framework.
- Scientists explore triggers associated with transplacental transmission of SARS-CoV-2
A new study examines the risk of fetal SARS-CoV-2 infection following infection of a pregnant mother with the virus.
- Philippines: Local transmission of Omicron BA.2.12.1 detected
Manila: The Philippines Department of Health (DOH) has detected a local transmission of the highly-transmissible Omicron subvariant BA.2.12.1, Health Undersecretary Maria Rosario Vergeire said Tuesday ...
- Vaccination boosted immunity acquired from previous SARS-CoV-2 infection
Two doses of the Pfizer-BioNTech BNT162b2 vaccine were linked to high immediate protection again severe acute respiratory syndrome coronary virus 2 (SARS-CoV02) infection, which waned after 6 months ...
- Adding mask recommendation did not significantly reduce the SARS-CoV-2 infection rate
Adding a mask recommendation to other public measures did not reduce the SARS-Cov-2 infection by more than 50%. 2. Having a mask recommendation did not significantly alter the SARS-CoV-2 infection ...